外周T细胞淋巴瘤
淋巴瘤
医学
间变性大细胞淋巴瘤
肿瘤科
T细胞淋巴瘤
切碎
内科学
正电子发射断层摄影术
未另行规定
滤泡性淋巴瘤
微小残留病
T细胞
核医学
免疫学
白血病
免疫系统
作者
Lauren Shea,Neha Mehta‐Shah
出处
期刊:Blood
[American Society of Hematology]
日期:2023-12-24
标识
DOI:10.1182/blood.2023020912
摘要
Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of mature T-cell neoplasms that represent approximately 10% of all non-Hodgkin Lymphoma (NHL). Outcomes for the majority of patients with PTCL are poor and treatment approaches have been relatively uniform using CHOP based therapy. For example, large registry studies consistently demonstrate 5-year overall survival (OS) of approximately 30-40%. However, as our understanding of the biology underpinning the heterogeneity of PTCL improves, and as treatments specifically for PTCL are developed, risk stratification has become a more relevant question. Tools including positron emission tomography-computed tomography (PET-CT) and minimal residual disease (MRD) monitoring offer the potential for dynamic risk stratification. In this review, we will first summarize registry data describing outcomes in the most common subtypes of PTCL - PTCL not otherwise specified (PTCL-NOS), nodal T-follicular helper cell lymphoma including angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large cell lymphoma (ALCL). We will describe current clinically based prognostic indices validated in PTCL and then highlight emerging tools for prognostication including novel molecular biomarkers, imaging-based metrics, and MRD dynamics.
科研通智能强力驱动
Strongly Powered by AbleSci AI